A Peek at InMode's Future Earnings
InMode (NASDAQ:INMD) is gearing up to announce its quarterly earnings on Tuesday, 2026-02-10. Here's a quick overview of what investors should know before the release.
Analysts are estimating that InMode will report an earnings per share (EPS) of $0.43.
Investors in InMode are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Performance in Previous Earnings
During the last quarter, the company reported an EPS beat by $0.06, leading to a 0.62% drop in the share price on the subsequent day.
Here's a look at InMode's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.32 | 0.40 | 0.35 | 0.50 |
| EPS Actual | 0.38 | 0.47 | 0.31 | 0.42 |
| Price Change % | -1.00 | -2.00 | 1.00 | 3.00 |
Tracking InMode's Stock Performance
Shares of InMode were trading at $15.08 as of February 06. Over the last 52-week period, shares are down 19.05%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
Analysts' Take on InMode
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding InMode.
Analysts have provided InMode with 1 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $15.0, suggesting a potential 0.53% downside.
Comparing Ratings Among Industry Peers
In this analysis, we delve into the analyst ratings and average 1-year price targets of Butterfly Network, CeriBell and NovoCure, three key industry players, offering insights into their relative performance expectations and market positioning.
- Analysts currently favor an Buy trajectory for Butterfly Network, with an average 1-year price target of $5.25, suggesting a potential 65.19% downside.
- Analysts currently favor an Buy trajectory for CeriBell, with an average 1-year price target of $30.0, suggesting a potential 98.94% upside.
- Analysts currently favor an Buy trajectory for NovoCure, with an average 1-year price target of $28.5, suggesting a potential 88.99% upside.
Insights: Peer Analysis
The peer analysis summary presents essential metrics for Butterfly Network, CeriBell and NovoCure, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| InMode | Neutral | -28.46% | $72.31M | 3.41% |
| Butterfly Network | Buy | 4.51% | $-3.76M | -15.56% |
| CeriBell | Buy | 31.37% | $19.94M | -8.01% |
| NovoCure | Buy | 7.81% | $122.47M | -10.79% |
Key Takeaway:
InMode ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
About InMode
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
Financial Insights: InMode
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: InMode's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2025, the company experienced a revenue decline of approximately -28.46%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: InMode's net margin excels beyond industry benchmarks, reaching 23.47%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.41%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.03%, the company showcases effective utilization of assets.
Debt Management: InMode's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
To track all earnings releases for InMode visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.